Australia's most trusted
source of pharma news
Monday, 01 December 2025
Posted 1 December 2025 AM
Pharmacor has launched an assault on A Menarini's Adenuric, registering four generic brands, Adenubex, Febexic, Uribexo, and Febuxostat Pharmacor, on the ARTG.
It's the first time the treatment - for chronic symptomatic hyperuricaemia in conditions where urate deposition has already occurred in adults with gout - has seen a competitor registered by the TGA.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.